<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1435">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04377568</url>
  </required_header>
  <id_info>
    <org_study_id>1000070143</org_study_id>
    <nct_id>NCT04377568</nct_id>
  </id_info>
  <brief_title>Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children</brief_title>
  <acronym>CONCOR-KIDS</acronym>
  <official_title>A Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus- Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>C17 Council (regulatory sponsor)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentered, open-label, randomized controlled Phase 2 trial to evaluate the
      safety and efficacy of providing human coronavirus-immune convalescent plasma as treatment
      for COVID-19 disease in hospitalized children in the context of the COVID-19 pandemic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SARS-CoV-2 viral infection resulting in COVID-19 disease has recently been designated by the
      World Health Organization as a global pandemic. Outbreak forecasting and mathematical models
      suggest that the number of COVID-19 cases will continue to rise over the coming weeks and
      months. There is an urgent public health need for rapid development of novel interventions.
      This protocol aims to use passive antibody therapy via convalescent plasma from
      SARS-CoV-2-infected patients who have developed antibody immunity, COVID-19 convalescent
      plasma (C19-CP), as treatment for hospitalized children with COVID-19 disease at pediatric
      academic hospitals across Canada. The unknown role for convalescent plasma in treating
      COVID-19 necessitates further study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to receive either standard of care (SoC) products (control) or COVID-19 convalescent plasma (C19-CP) plus standard of care while being hospitalized for COVID-19 (ratio 1:2). The intervention will consist of a single transfusion of convalescent plasma.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical recovery</measure>
    <time_frame>at day 30</time_frame>
    <description>defined in the last 24 hours as normal respiratory and heart rate (or return to baseline, absence of fever, absence of low blood pressure, oxygen saturation greater than 94% or room air (or return to baseline), no need for intravenous fluids (or return to baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined mortality/intubation</measure>
    <time_frame>at 30 day</time_frame>
    <description>Proportion of patients experiencing death in hospital (Yes/No) 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory status-1</measure>
    <time_frame>at 30 days</time_frame>
    <description>Proportion of patients experiencing Intubation (Yes/No)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory status-2</measure>
    <time_frame>time from admission to intubation</time_frame>
    <description>time to intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory status-3</measure>
    <time_frame>from admission to day 30 of hospitalization</time_frame>
    <description>Mean number of ventilator-free days in 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory status -4</measure>
    <time_frame>from admission to day 30 of hospitalization</time_frame>
    <description>Mean number of ventilator days in 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory status -5</measure>
    <time_frame>from admission to day 30 of hospitalization</time_frame>
    <description>The number of oxygen free days in the first 30 days or the incidence and duration of new oxygen use during the trial, defined as oxygen use that was not present at time of randomization but occurs subsequently</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory status-6</measure>
    <time_frame>at 30 days</time_frame>
    <description>The proportion of patients needing ECMO in 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality 1a</measure>
    <time_frame>at 30 days</time_frame>
    <description>Time to in-hospital death censored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality 1b</measure>
    <time_frame>at 90 days</time_frame>
    <description>Time to in-hospital death censored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality 2a</measure>
    <time_frame>at 30 days</time_frame>
    <description>Proportion of patients with Survival status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality 2b</measure>
    <time_frame>at 90 days</time_frame>
    <description>Proportion of patients with Survival status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Care and Critical Care</measure>
    <time_frame>at 30 days</time_frame>
    <description>Length of hospitalization and stay in the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>organ systems: renal</measure>
    <time_frame>up to 365 days</time_frame>
    <description>The proportion of patients needing renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>organ systems: cardiac</measure>
    <time_frame>up to 365 days</time_frame>
    <description>The proportion of patients developing myocarditis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion-associated adverse events (AE)</measure>
    <time_frame>up to 365 days</time_frame>
    <description>The proportion of patients developing adverse events to the treatment arm, C19-CP as assessed by Proposed Standard definitions for surveillance of non-infectious adverse transfusion reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the intervention</measure>
    <time_frame>up to 365 days</time_frame>
    <description>cumulative incidence of severe and life-threatening AEs and severe AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>organ systems: multi-system inflammatory disease</measure>
    <time_frame>up to 365 days</time_frame>
    <description>The proportion of patients developing multi-system inflammatory disease</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Virological measures 1</measure>
    <time_frame>at day 3</time_frame>
    <description>Proportion of patients with negative virology</description>
  </other_outcome>
  <other_outcome>
    <measure>Virological measures 3</measure>
    <time_frame>at day 10</time_frame>
    <description>Proportion of patients with negative virology</description>
  </other_outcome>
  <other_outcome>
    <measure>Virological measures 4</measure>
    <time_frame>at day 15</time_frame>
    <description>Proportion of patients with negative virology</description>
  </other_outcome>
  <other_outcome>
    <measure>Modulation of biomarkers</measure>
    <time_frame>up to 365 days</time_frame>
    <description>Exploratory analysis of biomarker differences between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Resolution of fever</measure>
    <time_frame>hours</time_frame>
    <description>Time to fever resolution (no longer requiring fever management)</description>
  </other_outcome>
  <other_outcome>
    <measure>Presence and titres levels</measure>
    <time_frame>at day 30</time_frame>
    <description>Presence and titres of IgG, IgA antibodies and neutralizing antibody titres in C19-CP group on the primary outcome and other outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional measure 1</measure>
    <time_frame>up to 365 days</time_frame>
    <description>efficacy of C19-CP on respiratory measures using pediatric validated dyspnea (breathlessness) scales</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional measure 2</measure>
    <time_frame>up to 365 days</time_frame>
    <description>Evaluate the efficacy of C19-CP on quality of life (QOL) measures using Validated QOL scores (Eq-5D)</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional measure 3</measure>
    <time_frame>up to 365 days</time_frame>
    <description>Evaluate the efficacy of C19-CP on rehospitalization after discharge</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hospitalized Children</condition>
  <condition>Covid-19 Infection</condition>
  <arm_group>
    <arm_group_label>Convalescent Plasma + Standard of Care (C19-CP + SoC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive COVID-19 convalescent plasma (C19-CP) plus standard of care while being hospitalized for COVID-19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care (SoC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will receive standard of care while being hospitalized for COVID-19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma (CP)</intervention_name>
    <description>Participants will receive one infusion of convalescent plasma proportional to their weight (10 mL/kg), up to a maximum of 500 mL</description>
    <arm_group_label>Convalescent Plasma + Standard of Care (C19-CP + SoC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 0 to &lt;19 years old

          2. Hospitalized with symptoms compatible with COVID-19 illness

          3. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or
             public health assay in any specimen prior to randomization.

          4. ABO compatible convalescent plasma available

        Exclusion Criteria:

          1. Onset of symptoms began &gt;12 days before screening

          2. History of adverse reactions to blood products or other contraindication to
             transfusion

          3. Refusal of plasma for religious or other reasons

          4. Acute heart failure with fluid overload

          5. Any condition or diagnosis, that could in the opinion of the Site Principal
             Investigator interfere with the participant's ability to comply with study
             instructions, or put the participant at risk

          6. Anticipated discharge within 24 hours

        Note: The intent of this exclusion criteria is to only include participants with acute
        COVID-19 infections. This protocol is not intended to include participants with
        post-infectious complications. In cases where the distinction is not clear, participant
        eligibility will be discussed with the study steering committee prior to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Upton, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathy Brodeur-Robb</last_name>
    <role>Study Director</role>
    <affiliation>C17 Council (regulatory sponsor)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Upton</last_name>
    <phone>416 813 7654</phone>
    <phone_ext>208634</phone_ext>
    <email>julia.upton@sickkids.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Licht</last_name>
    <email>christoph.licht@sickkids.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Tammie Dewan</last_name>
      <phone>403-955-2251</phone>
      <email>tammie.dewan@ahs.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Ari Joffe</last_name>
      <phone>780-904-5003</phone>
      <email>ari.joffe@ahs.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Kyla Hildebrand</last_name>
      <phone>604-875-2118</phone>
      <email>kyla.hildebrand@cw.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winnipeg Children's Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Sergio Fanella</last_name>
      <phone>204-789-3619</phone>
      <email>Sergio.fanella@umanitoba.ca</email>
    </contact>
    <contact_backup>
      <last_name>Geoff Cuvelier Cuvelier</last_name>
      <phone>204-787-8689</phone>
      <email>gcuvelier@cancercare.mb.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Karina Top</last_name>
      <phone>902-470-6343</phone>
      <email>karina.top@dal.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Carol Portwine</last_name>
      <phone>905 521-2100</phone>
      <phone_ext>73440</phone_ext>
      <email>portwc@mcmaster.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Kirk Leifso</last_name>
      <phone>613-549-6666</phone>
      <phone_ext>4088</phone_ext>
      <email>Kirk.leifso@kingstonhsc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 2V5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Nancy Nashid</last_name>
      <phone>289-684-3659</phone>
      <email>nancy.nashid@lhsc.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne Pham-Huy</last_name>
      <phone>613 737-7600</phone>
      <phone_ext>2651</phone_ext>
      <email>aphamhuy@cheo.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter Gill, MD</last_name>
      <phone>4168137654</phone>
      <phone_ext>208634</phone_ext>
      <email>peter.gill@sickkids.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Julie Autmizguine</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>5566</phone_ext>
      <email>julie.autmizguine@umontreal.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill Univ Health Ctr - Montreal Children's Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Jesse Papenburg</last_name>
      <phone>514 412-4400</phone>
      <email>jesse.papenburg@mail.mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Rupeena Purewal</last_name>
      <phone>306-844-1249</phone>
      <email>rupeena.purewal@saskhealthauthority.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Julia Upton</investigator_full_name>
    <investigator_title>Staff Physician, Allergy and Immunology</investigator_title>
  </responsible_party>
  <keyword>covid-19</keyword>
  <keyword>hospitalized children</keyword>
  <keyword>convalescent plasma therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

